Georg Schett, MD, presented the latest research into CAR T cell therapy for rheumatic diseases, such as systemic lupus erythematosus & other conditions. These findings demonstrate remarkable and durable efficacy for the treatment, as well as the potential for disease remission in some patients.
The complexity add-on code is appropriate to bill for an evaluation and management visit related to a transient or temporary problem when there is an established relationship for ongoing longitudinal care, even if the ongoing care is unrelated to the transient problem being treated.
The program will take place May 5–7 in conjunction with the ACR Advocacy Leadership Conference in Washington, DC. Fellows in training, program directors and ARP members passionate about advocacy and governance are especially encouraged to apply
State rheumatology society meetings provide many opportunities and benefits for rheumatology professionals, including networking and collaboration opportunities, skill enhancement, regulatory updates and leadership development.
SAN DIEGO—As part of a panel on systemic autoinflammatory diseases (SAIDs) at a Nov. 15 scientific session of ACR Convergence 2023, Sivia Lapidus, MD, shared context and insights on the therapeutic management of patients with these conditions. The Spectrum of SAIDs SAIDs encompass a broad swath of individually rare disorders driven by innate immune responses…
SAN DIEGO—In one presentation at Plenary Session 3, ACR Convergence 2023, Beth Wallace, MD, MSc, a staff physician at the VA Ann Arbor Healthcare System, Michigan, and an assistant professor at the University of Michigan, Ann Arbor, shared important data on the relationship between time-dependent cumulative glucocorticoid exposure and major adverse cardiovascular events (MACE) in a cohort of veterans with rheumatoid arthritis (RA).
After three years on the Committee for Research, Linda Hiraki, MD, ScD, has stepped into the role of chair. During her term, she aims to foster global connections to advance and expand the positive impact of rheumatology research.
Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.
In this episode, Dr. Bharat Kumar, physician editor of The Rheumatologist, goes on the record with his predictions for how rheumatology will change in the next 10 years.
In this episode, Dr. Bharat Kumar, physician editor of The Rheumatologist, discusses the definition of empathy and its role in rheumatology.